Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
OCS
#5227
Oculis Holding AG - Ordinary shares
12.2
7
USD
-0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.29%
Monthly Change
+10.94%
6 month change
-57.41%
Year Change
-25.05%
Previous Close
12.4
3
Open
12.2
2
Low
12.2
2
High
12.3
0
Volume
44
Markets
US Stock Market
Healthcare
Biotechnology
OCS
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
3.41 M
—
—
—
—
Valuation ratios
Enterprise value
—
—
—
—
—
Price to earnings ratio
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
Price to book ratio
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
Return on equity %
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
Gross margin %
—
—
—
—
—
Operating margin %
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
Net margin %
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
—
—
—
—
—
Inventory turnover
—
—
—
—
—
Asset turnover
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
Working capital per share
—
—
—
—
—
Book value per share
—
—
—
—
—
News
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates
Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating (NASDAQ:OCS)
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
H.C. Wainwright raises Oculis stock price target to $44 on trial progress
Stifel raises Oculis stock price target to $50 on pipeline progress
Oculis Holding AG renews $100 million at-the-market offering program
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript